Data as of Sep 17
| +0.64 / +2.87%|
The 15 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 37.00, with a high estimate of 63.00 and a low estimate of 13.00. The median estimate represents a +61.29% increase from the last price of 22.94.
The current consensus among 16 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.